Jump to content

Talk:Multiple myeloma: Difference between revisions

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
Added financial disclosure to top of page
Line 13: Line 13:
| minthreadstoarchive=1
| minthreadstoarchive=1
}}
}}
{{Connected contributor (paid)|User1=Cglife.trummler|U1-employer=CG Life|U1-client=Impact Journals}}.


== Reviews ==
== Reviews ==

Revision as of 22:44, 14 November 2017

WikiProject iconMedicine: Hematology-oncology B‑class Mid‑importance
WikiProject iconThis article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
BThis article has been rated as B-class on Wikipedia's content assessment scale.
MidThis article has been rated as Mid-importance on the project's importance scale.
Taskforce icon
This article is supported by the Hematology-oncology task force.
WikiProject iconVeterinary medicine Start‑class Mid‑importance
WikiProject iconThis article is within the scope of WikiProject Veterinary medicine, a collaborative effort to improve the coverage of Veterinary medicine on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Veterinary medicineWikipedia:WikiProject Veterinary medicineTemplate:WikiProject Veterinary medicineVeterinary medicine
StartThis article has been rated as Start-class on Wikipedia's content assessment scale.
MidThis article has been rated as Mid-importance on the project's importance scale.

.

Reviews

Numerous translational reviews in Blood this week: http://bloodjournal.org/content/125/20 - 15 May 2015‎

Double-up: Initial Therapy

In the line:


The most common induction regimens used today are lenalidomide–dexamethasone, bortezomib based regimens, and lenalidomide–dexamethasone.[29][30]


There is a double-up of 'lenalidomide'. One should be 'thalidomide'.


I fear my (complete) lack of wiki skill would cause issues, so I have noted this in the hope someone else can fix.


Cheers! — Preceding unsigned comment added by 110.175.168.126 (talk) 13:59, 4 October 2016 (UTC)[reply]

BCSH

Late and long term complications of myeloma and its treatment: guideline doi:10.1111/bjh.14514 JFW | T@lk 12:05, 24 January 2017 (UTC)[reply]

Refractory and relapsed disease

Network meta-analysis doi:10.1182/bloodadvances.2016003905 JFW | T@lk 20:28, 13 March 2017 (UTC)[reply]

Relapse

Proposed edit: Following the sentence "Bortezomib is a proteasome inhibitor," add, "Identifying the levels of specific proteins may help doctors identify whether a patient will benefit from a proteasome inhibitor." Citation: DOI: 10.18632/oncoscience.356

I'd like to open this to discussion because the citation is primary research, so not ideal. However, the first sentence does not give readers any context as the significance of being a proteasome inhibitor or how physicians use that information. The purpose of this edit would be to help fill that gap. Thoughts? Cglife.trummler (talk) 22:43, 14 November 2017 (UTC)[reply]

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Talk:Multiple_myeloma&oldid=810384200"